Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:REPL

Replimune Group Q2 2027 Earnings Date & Estimates

Replimune Group logo
$13.42 +0.38 (+2.91%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$13.41 -0.01 (-0.07%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group is expected to report Q2 2027 earnings on Thursday, November 5, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q2 2027
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Replimune Group in Q2 2027

Replimune Group is expected to post earnings of -$0.7840 per share on revenue of $1.00 million. In the same quarter a year earlier Replimune Group reported -$0.90 per share. Replimune Group last reported on August 14, 2026, posting -$0.72 per share and missing the -$0.6940 consensus estimate. Replimune Group has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.7840
Expected Revenue
$1.00 million
Prior-Year EPS
-$0.90

Recent Track Record

Last Reported
Q1 2027
Last Quarter EPS
-$0.72 (Missed by -$0.0260)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q2 2027 Call

Replimune Group Q2 2027 Earnings FAQ

Replimune Group (NASDAQ:REPL) is estimated to report Q2 2027 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Replimune Group's Q2 2027 earnings conference call is scheduled for Friday, November 13, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Replimune Group to post earnings of -$0.7840 per share for Q2 2027.

The consensus revenue estimate for Replimune Group is $1.00 million for Q2 2027.

Replimune Group Earnings Headlines

Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus
October 9 at 12:50 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/replimune-group-repl-launches-tudriqev-151227981.html
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374835/9788/en/bronstein-gewirtz-grossman-llc-urges-replimune-group-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
October 10 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Replimune Group, Inc. Announces Tudriqev? Now Commercially Available in the United States for Advanced Melanoma
October 2, 2026  |  marketscreener.comM
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373980/0/en/replimune-class-action-deadline-monday-bragar-eagel-squire-p-c-urgently-reminds-replimune-group-inc-investors-to-contact-the-firm-seeking-lead-plaintiff-role-before-october-5th.html
Replimune Receives Approval to Launch Tudriqev in the US for Melanoma
October 1, 2026  |  marketscreener.comM
See More Replimune Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email.

About Replimune Group

Replimune Group (NASDAQ:REPL) is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company’s approach uses genetically engineered viruses designed to selectively replicate in tumors, directly destroy cancer cells and stimulate a broader immune response against malignant tissue.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 intended for use in patients with advanced solid tumors. The company has evaluated RP1 as a standalone therapy and in combination with immune checkpoint inhibitors. Its pipeline has also included additional investigational oncolytic immunotherapies, including RP2 and RP3, which are designed with different payloads and mechanisms to enhance antitumor immune activity.

Founded in 2015, Replimune is headquartered in the United States and conducts clinical development through research and collaborations involving patients with advanced cancers in multiple regions. The company’s programs remain focused on advancing novel immunotherapies through clinical testing and potential regulatory approval.

View Replimune Group Profile
Earnings Tools